Open Access<p>PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate</p>
Author(s) -
Sofía España,
Maria Ochoa de Olza,
Núria Sala,
Josep María Piulats,
U. Ferrándiz,
Olatz Etxániz,
L Heras,
O. Buisán,
Juan Carlos Pardo,
José Francisco Suárez,
Maria-Pilar Barretina-Ginesta,
Josep Comet,
Xavier García del Muro,
Lauro Sumoy,
Albert Font
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s270392
Subject(s) - medicine , prostate cancer , docetaxel , prostate specific antigen , abiraterone acetate , univariate analysis , oncology , urology , androgen deprivation therapy , multivariate analysis , cancer
Abiraterone acetate (AA) is widely used in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, a significant percentage of patients will still progress, highlighting the need to identify patients more likely to benefit from AA. Parameters linked to prostate-specific antigen (PSA) kinetics are promising prognostic markers. We have examined clinical and PSA-related factors potentially associated with overall survival (OS) in patients treated with AA.